WGBS Discovery Samples
The dataset contains valuable genomic data from a discovery cohort consisting of 29 individuals. This cohort is comprised of 8 healthy individuals (control), 8 patients with ST-segment elevation myocardial infarction (STEMI), 7 patients with non-ST-segment elevation myocardial infarction (NSTEMI), and 6 patients with unstable angina (UA). The genomic data was obtained by isolating cell-free circulating DNA (ccfDNA) and subjecting it to bisulfite conversion using a low-input BS-seq (PBAT) protocol. Sequencing was done on the Novaseq 6000 platform.
- 16 samples
- DAC: EGAC00001003283
- Technology: Illumina NovaSeq 6000
- DS DUO:0000007 (version: 2021-02-23)disease specific researchThis data use permission indicates that use is allowed provided it is related to the specified disease.ModifiersMONDO:0005542
- NPUNCU DUO:0000018 (version: 2021-02-23)not for profit, non commercial use onlyThis data use modifier indicates that use of the data is limited to not-for-profit organizations and not-for-profit use, non-commercial use.
- PS DUO:0000027 (version: 2021-02-23)project specific restrictionThis data use modifier indicates that use is limited to use within an approved project.
- NCU DUO:0000046 (version: 2021-02-23)non-commercial use onlyThis data use modifier indicates that use of the data is limited to not-for-profit use.
Policy for Controlled-Access Data Access establishes a framework for responsible and ethical access to controlled-access data
The Policy for Controlled-Access Data Access establishes a framework for responsible and ethical access to controlled-access data. By implementing a Data Access Committee and rigorous application review processes, the policy ensures the protection of privacy, confidentiality, and compliance with legal and ethical requirements. It emphasizes data security, responsible data governance, and transparent communication with applicants and stakeholders. Regular policy reviews and updates guarantee alignment with advancements in technology, regulations, and ethical standards. By adhering to this policy, the DAC facilitates access to controlled-access data for research purposes while prioritizing privacy, confidentiality, and the responsible use of data.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |